Table 3.
Characteristics of nivolumab‐related pneumonitis in patients with preexisting ILD
| Case | Age | Histology | ECOG‐PS | Radiographic pattern of | Category | Severity | Outcome | |
|---|---|---|---|---|---|---|---|---|
| Preexisting ILD | Pneumonitis | |||||||
| 1 | 72 | Squamous | 2 | UIP | AIP | Exacerbation | 3 | Improved |
| 2 | 76 | Adenocarcinoma | 1 | NSIP | AIP | Exacerbation | 4 | Improved |
| 3 | 72 | Adenocarcinoma | 0 | NSIP | COP | De novo | 1 | Improved |
| 4 | 69 | Squamous | 1 | UIP | COP | De novo | 3 | Improved |
| 5 | 62 | Squamous | 1 | UIP | AIP | Exacerbation | 3 | Progressed |
| 6 | 74 | Adenocarcinoma | 0 | NSIP | COP | De novo | 3 | Improved |
| 7 | 55 | Adenocarcinoma | 1 | NSIP | NSIP | Exacerbation | 1 | No change |
| 8 | 65 | Squamous | 0 | NSIP | COP | De novo | 1 | Improved |
All patients were male and current or former smokers. The severity of interstitial lung disease (ILD) was evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.
AIP, acute interstitial pneumonia; COP, cryptogenic organizing pneumonia; NSIP, non‐specific interstitial pneumonia; UIP, usual interstitial pneumonia.